Build the future of personalized health together.
BioTwin partners with healthcare systems, pharma, research institutions, and investors to deploy clinical decision support technology in clinical validation, powered by virtual twin methodology.
Clinical partnerships are limited by jurisdiction. Clinical availability: UAE only, through participating physicians in authorized settings. BioTwin is not authorized as a medical device in Canada or the United States.
Primary care, hospitals, wellness centers
Deploy clinical decision support tools for preventive care, risk stratification, and longitudinal clinical development and follow-up workflows. BioTwin augments physician judgment with Bio-Signature insights while clinical authority remains fully with the treating provider.
Clinical partnerships are limited by jurisdiction. Clinical availability: UAE only, through participating physicians in authorized settings. BioTwin is not authorized as a medical device in Canada or the United States.
What partners receive:
- Clinical pilots with structured validation
- Multi-domain screening pathways
- Patient retention and engagement
- Physician-led decision support
Drug development, RWE, endpoint prediction
Leverage virtual twins for patient stratification, clinical trial optimization, and real-world evidence generation. BioTwin models are being developed to support patient stratification.
What partners receive:
- Patient selection and enrichment
- Predictive endpoint modeling
- Longitudinal clinical development and follow-up workflows
- Regulatory-grade evidence
Academic hospitals, think tanks, NIH
Co-develop virtual twin methodology through joint research, data collaborations, and peer-reviewed publications. BioTwin works with academic partners to advance the science of longitudinal personalized health.
What partners receive:
- Co-authorship pathways
- Federated multi-site analysis
- Technology transfer licensing
- Grant collaboration
How to partner with BioTwin
A structured pathway from exploratory call to commercial deployment. Typical timeline: 3 to 6 months for pilot launch.
Exploratory call
1-hour strategy session to assess fit and objectives
Due diligence
Technical assessment, data review, and regulatory alignment
Pilot design
Define scope, KPIs, timeline, and success metrics
IRB & governance
Joint ethics review, consent framework, data agreements
Deployment
Pilot launch, training, and ongoing support
Scale
Validation outcomes, commercial terms, and expansion
Research ethics & governance
All BioTwin research and partnerships adhere to established ethical and regulatory standards. IRB approval, informed consent, and formal data governance agreements are required for all collaborations. Patient privacy, auditability, and data security are foundational.
Ready to start a partnership conversation?
Submit your partnership inquiry. The BioTwin team will review and respond within 48 hours.
One account across BioTwin and TwinMe. No second sign-up required.